Live tape
Top 8, mentions 7d14,338NVDA4,854 mentions▲ +0.04GOOGL2,061 mentions▲ +0.04SPY1,736 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,106 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK861 mentions▲ +0.05

Equity · Healthcare

AVBP

NASDAQ

ArriVent BioPharma (AVBP)

14.15 USD +3.55% vs prior close Nov 9, 2026
ArriVent BioPharma, Inc. price graph
63 sessions
40 10 12 Aug 9 Nov

The line runs 31.45 USD on 12 August through 14.15 USD on 9 November, on a scale from 10 to 40. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView
Market cap
731.6M USD
EPS, diluted, year to Dec 2025
−4.32 USD
52-week range
12.21 USD – 34.75 USD
Avg volume
121.6K

as of Nov 9, 2026

Have ArriVent BioPharma (AVBP) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, no ArriVent BioPharma insider bought or sold shares on the open market; the 1 Form 4 filing in that window was a grant, exercise, tax withholding or transfer (SEC Form 4).

Form 4, 90 days to 10 Nov 2026, newest Form 4 filing 30 Oct 2026

0buys
0sells
1other filings
Have ArriVent BioPharma (AVBP) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
30 Oct 2026LaChapelle RobinChief Operating OfficerOption exercise40,693185K USD

Which funds hold ArriVent BioPharma (AVBP)?

8 of the 45 institutional funds we track reported a ArriVent BioPharma position for the quarter ended 30 Jun 2026 — a combined 88.0M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold ArriVent BioPharma (AVBP)?
FundPositionSharesValueShares q/q
D. E. Shaw & Co.Added872,01130.3M USD+136.4%
Point72 Asset ManagementHeld (±25%)566,79619.7M USD−24.2%
Millennium ManagementHeld (±25%)438,66415.2M USD+3.0%
Balyasny Asset ManagementHeld (±25%)395,44713.7M USD−7.2%
Citadel AdvisorsHeld (±25%)156,7425.4M USD−5.7%
Two Sigma InvestmentsHeld (±25%)57,8042.0M USD+18.7%
Tudor Investment CorpHeld (±25%)23,287809K USD+5.4%
AQR Capital ManagementAdded21,517748K USD+35.1%
Man GroupExited
Marshall WaceExited

What has been filed or recorded for ArriVent BioPharma (AVBP)?

The filings we hold for ArriVent BioPharma, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for ArriVent BioPharma (AVBP)?
And
13 Oct 2026Fails to deliverShares failed to deliver280 shares5K USD notional · 0.001% of shares out
09 Oct 2026Fails to deliverShares failed to deliver80 shares1K USD notional · <0.001% of shares out
07 Oct 2026Fails to deliverShares failed to deliver206,555 shares3.1M USD notional · 0.419% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.81 USD
30 Sep 2026FinancialsTotal assets417.1M USDat period end
30 Sep 2026FinancialsTotal equity393.5M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −1.05 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.96 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −4.32 USD
31 Dec 2025FinancialsNet income−166.3M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−4.32 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.83 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.90 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −1.90 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −2.56 USD

What do people ask about ArriVent BioPharma (AVBP)?

From live data
What did ArriVent BioPharma shares close at?14.15

ArriVent BioPharma closed at 14.15 USD on 9 Nov 2026, up 3.55% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is ArriVent BioPharma’s market cap?731.6M

ArriVent BioPharma is worth 731.6M USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.

Have ArriVent BioPharma insiders bought or sold shares recently?1 filing

In the 90 days to 10 Nov 2026, no ArriVent BioPharma insider bought or sold shares on the open market; the 1 Form 4 filing in that window was a grant, exercise, tax withholding or transfer (SEC Form 4). See Insiders

Which funds own ArriVent BioPharma?8 of 45

8 of the 45 funds we track reported a ArriVent BioPharma position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were D. E. Shaw & Co., Point72 Asset Management and Millennium Management. See Funds

When did ArriVent BioPharma last report earnings?−0.81

ArriVent BioPharma last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.81 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings